Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.54 |
| ▸ | CDC7 | O00311 | 8/20 | 0.53 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046763 | 0.92 | MAPT (0.61) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL27717711 | 0.91 | MAPT (0.70) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL4484447 | 0.91 | MAPT (0.76) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL4804421 | 0.91 | MAPT (0.76) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL4467429 | 0.89 | MAPT (0.74) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL4809764 | 0.89 | MAPT (0.74) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL4468293 | 0.88 | MAPT (0.73) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL14394668 | 0.88 | MAPT (0.73) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL2886264 | 0.87 | TRPM8 (0.71) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL6756856 | 0.87 | MAPT (0.75) | MAPTMEN1KMT2AKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006922-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| EP-1368011-A1 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1349843-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003072102-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002059098-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | PPARG, PPARA, PPARD | MAPT 3868/4885MEN1 4636/4885KMT2A 3543/4885 |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | PPARA, PPARG, PPARD | MAPT 4132/4885MEN1 4401/4885KMT2A 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.